Did you know?
ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.
Free Newsletter
Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!
Free Report
Week in Review: Agilent Pays $250 Million to Acquire ACEA and its Cell Therapy Analyzer
Deals and Financings
ACEA Biosciences, a San Diego company with R&D and manufacturing facilities in Hangzhzou, will be acquired by Agilent (NYSE: A) for $250 million in cash (see story). ACEA has developed the xCELLigence® cell therapy analysis device intended for academic and biopharma researchers. The device is used in immuno-oncology, pre-clinical drug discovery and basic academic research. In 2015, ACEA raised $30 million from
Zhejiang Anglikang Pharmaceutical, headquartered in Shengzhou, has been approved to stage an $87 million IPO on the Shenzhen SME (small- and medium-sized enterprise) Exchange (see story). The company is mainly known as a cephalosporin manufacturer with an annual capacity of 1500 tons. It also makes angiography and gastrointestinal drugs. Founded in 1994, Anglikang produces finished drugs, APIs and empty gelatin capsules and has annual revenues of over $150 million.
CSPC Pharmaceutical (HK: 1093) in-licensed
Cellular Biomedicine (NSDQ: CBMG) will provide
Bellen Chemistry, a Beijing CRO/CMO, raised "hundreds of millions in RMB" ($30 million plus) in a C financing round (see story). The company offers chemical synthesis for chemical drugs based on its large library of heterocycles. Founded in 2007, Bellen has its headquarters and a research lab in
Jinzhou Ahon Pharma, a subsidiary of Shanghai Fosun Pharma (HK: 02196: SHA: 600196), in-licensed greater
WuXi Biologics (HK: 2269) formed a collaboration with I-Mab Biopharma to develop three bi-specific antibodies, using WuXi's proprietary WuXiBody™ Platform to discover, develop and commercialize the three antibodies (see story). I-Mab will make an unspecified upfront payment to
Flow Pharma, a San Francisco Bay Area biotech, formed a China JV with Button Capital to conduct
Everest Medicines II, a US-China in-licensing company, acquired
Disclosure: none.
ChinaBio® News
Greg Scott Interviewed at BIO-Europe Spring
How to bring your China assets to China in 8 minutes
"Mr. Bio in China."
Mendelspod Interview
Multinational pharma held to a higher standard in China